Evidence map›Paper›PMID 41341657›Full record

ArticleThe Lancet regional health. Western Pacific2025

Smartphone based cognitive behavioural therapy for adults with no or minimal depressive symptoms in Japan: an exploratory secondary analysis of RESiLIENT trial.

Rie Toyomoto, Aran Tajika, Yan Luo, Masatsugu Sakata, Tatsuo Akechi, Takeo Nakayama, Naoki Kondo, Shingo Fukuma, Masaru Horikoshi, James M S Wason and 2 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rie ToyomotoDepartment of Health Promotion and Human Behaviour, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Aran TajikaDepartment of Health Promotion and Human Behaviour, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Yan LuoDepartment of Health Promotion and Human Behaviour, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Masatsugu SakataDepartment of Health Promotion and Human Behaviour, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioural Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takeo NakayamaDepartment of Health Informatics, School of Public Health, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Naoki KondoDepartment of Social Epidemiology, School of Public Health, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shingo FukumaHuman Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Masaru HorikoshiDepartment of Human Sciences, Musashino University, Tokyo, Japan.
James M S WasonPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Hisashi NomaDepartment of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tokyo, Japan.
Toshi A FurukawaKyoto University Office of Institutional Advancement and Communications, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although cognitive behavioural therapy (CBT) is a well-established intervention for both the prevention and treatment of depression, its potential role in mentally healthy individuals remains underexplored. We aimed to evaluate the effects of smartphone CBT in mentally healthy adults. Methods: This exploratory secondary analysis from the RESiLIENT trial (UMIN000047124), a master protocol trial consisting of four 2 × 2 factorial trials, included 1,425 adults with no or very mild depressive symptoms (PHQ-9 ≤4). Participants were recruited nationwide and randomly assigned via a centralized web-based system to one of 12 six-week programs (n = 117 to 120 each): five single-skill CBT interventions (Behavioural Activation [BA], Cognitive Restructuring [CR], Problem Solving [PS], Assertion Training [AT] and Behaviour therapy for Insomnia [BI]), 4 combinations in which BA was paired with another skill, and three control conditions (Health Information [HI], Self-check [SC], Delayed Treatment [DT]). HI, serving as the primary comparator, delivered general health information in a format similar to active interventions. The primary outcome was change in depressive symptoms (PHQ-9) from baseline to weeks 6 and 26. Secondary outcomes included anxiety (GAD-7), insomnia (ISI), and well-being (SWEMWBS). Findings: The follow-up rate was 96% at week 6 and adherence to the app was 83%. At week 6, all interventions except PS and BA + PS were superior to HI (SMDs -0.62 to -0.22). At week 26, BA, AT and BI or BA + CR appeared to retain moderate efficacy (SMDs -0.30 to -0.27). BA and AT reduced anxiety, and AT and BI improved sleep quality at week 6. In contrast, CR and PS showed limited effects and lower adherence. There was insufficient evidence to show that the interventions improved overall well-being. No serious adverse events were reported. Interpretation: Single-skill smartphone CBT, especially BA and AT, reduced depressive and anxiety symptoms in healthy adults, supporting its use as a scalable public health prevention tool and suggesting that the efficacy of individual CBT skills may differ based on baseline symptom severity, highlighting the importance of tailored interventions for mental health maintenance. Funding: This study was supported by AMED (grant no. JP21de0107005) and JSPS KAKENHI (grant no. 22K21171).

Indexed as

CBT component analysisDepression preventionMental health promotionTelemedicine

Identifiers

PMID41341657
PMCPMC12670958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.